Last reviewed · How we verify
Azienda Ospedaliera V. Cervello — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin | PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin | marketed | ||||
| Deferiprone (DFP) | Deferiprone (DFP) | marketed | Iron chelator | Ferric iron (Fe³⁺) | Hematology |
Therapeutic area mix
- Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- ApoPharma · 1 shared drug class
- Consorzio per Valutazioni Biologiche e Farmacologiche · 1 shared drug class
- CorMedix · 1 shared drug class
- The George Institute · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliera V. Cervello:
- Azienda Ospedaliera V. Cervello pipeline updates — RSS
- Azienda Ospedaliera V. Cervello pipeline updates — Atom
- Azienda Ospedaliera V. Cervello pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliera V. Cervello — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-v-cervello. Accessed 2026-05-17.